KULTURA BRANDS (OTCID: LTNC) ANNOUNCES OFFICIAL LAUNCH ELEVATE HEALTH & WELLNESS GUMMIES NOW AVAILABLE FOR B2B THROUGH CENCORA MARKETPLACE AND DIRECT-TO-CONSUMER AT LOCKDIN.COM; THIRST RESPONDER HYDRATION LAUNCHES MID-DECEMBER; PORTION OF ALL SALES BENEFITS THE MANNY PACQUIAO FOUNDATION

~Funding supports Phase 3 clinical development of PF614 and continued innovation in abuse- and overdose-resistant analgesics~

Initial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure due to microvillus inclusion disease (MVID), reducing the volume of the total parenteral support (PS) necessary for them to survive, though with associated toxicity; Groundbreaking PS reduction of up to 37%; No approved treatments exist for MVID

Company completed meeting with FDA October 2, 2025 for advice on possible expedited approval pathway to advance its ongoing placebo-controlled trial of crofelemer for potential approval for treatment of MVID

• Strategic partnership between XCF Global and BGN to jointly develop global distribution and logistics infrastructure for SAF and other renewable fuels

• Seeks to expand XCF's international reach into key markets including Europe and the Middle East through production, offtake, and co-branded distribution agreements

• Advances global renewable fuel supply chains to meet rapidly rising demand for SAF

SKNJCT-003 Doxorubicin containing Microneedle Array (D-MNA) clinical development program to non-invasively treat BCC aligns with national priorities of public health impact, unmet medical need, access, affordability, domestic manufacturing and rare-disease alignment.

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Management Will Be Discussing Its Financial Results, Sources and Uses of Funding of $40.5 Million Closed on September 9, 2025, and Accomplishments and Plans for the Remainder of 2025

Record Net Income of $5.6 Million for the Quarter; Retired All $41 Million of Senior and Seller Debt; Retired All Preferred Shares with Redemption Value of $27 Million; and Increased Shareholder Equity by $22.7 Million

$4.5 Million Cash Balance at Quarter-End as High-Impact Technology Portfolio Advances

Featured companies include Lionscrest Advisors, DataVault AI (NASDAQ:DVLT), Pudgy Penguins (PENGU)), Peer To Peer Network (OTC:PTOP), and Acurx Pharmaceuticals (NASDAQ:ACXP).

IRAEmpire has published its new and updated rankings of the best silver IRA providers in the USA this year. The rankings are aimed at educating consumers to help them make better-informed decisions.

Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH antagonist, are steadily advancing

DL Hudson Applies for Administration to Facilitate Strategic Restructuring

~ Third Quarter Highlighted by Initiation of Phase 3 Study of PF614, Underscoring Progress Toward Market Readiness and Commitment to Novel Opioid Solutions ~

~ Further Program Advancement Supported by Preferred Stock Financing ~

- Dermata announced a strategic pivot to develop and commercialize over-the-counter (OTC) skin care treatments -

- Dermata plans to launch its first OTC product, a once weekly acne kit with its Spongilla technology, in the middle of 2026 -

Recognition Highlights ClearStar's Commitment to Excellence in Background Screening

With 6-figure expectations this one of one 2009 Topps Unique Tom Brady card featuring a game-worn NFL Equipment patch and autograph is now live at Fanatics Collect's Premier Auction that ends Thursday, November 20, 2025 at 9:30 PM Eastern Time (EST).

-Targets $3 Billion "Almost-Pumper" Market with First Simplified and Removable/Replaceable Insulin Patch Pump

- Aims to Improve Patient and Clinician Experience for the Care of Diabetes

• 125.6% increase in total revenue to $3.1 million compared to 3Q24

• 437.8% increase in gross profit to $1.9 million compared to 3Q24

• 209.9% increase in income from continuing operations to $643,000 compared to 3Q24

Quarterly Results Reflect First Full Quarter Including Wattbike (Acquisition Closed July 1)

Company Reports Record Quarterly Revenue of $4.8 Million; Net Loss and Loss per Diluted Share of $5.2 Million and $3.11; Quarterly Adjusted EBITDA Loss of $2.9 million, Due to Low Inventory Availability

Sportstech Acquisition Expected to Close in 2025 Based on Key Closing Milestone Achievements

Reiterates 2025 Pro Forma Revenue Guidance of more than $80 million and Fourth Quarter Profitability Guidance

Outdoor toy-drive event rescheduled to prioritize safety as Las Vegas faces 70-90% chance of rain on Saturday

Digital olfactory commercialization accelerates toward 2026 scale-up, as industrial partnerships expand to six and the IP moat strengthens.

World's first patented commercial AI Nose device launched, advancing SmellTech-as-a-Service adoption.

Net income from continuing operations of $5.9 million in Q3 2025

Gross margin increased 20.0% sequentially to 49.4%

Balance sheet at September 30, 2025, strongest in the Company's history with $81.5 million in DAT assets and cash, no debt and shareholders' equity of $78.7 million

Management expects continued positive momentum in Q4 2025